Wugen, Inc.
Last verified 2026-06-02. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $163.0Mattributed |
|---|---|
| Latest round | Funding round, $163.0M, 2025-09-08attributed |
| Founded | unknown |
| Headquarters | St. Louis, Missouri |
| Industry | health care |
| Stage | unknown |
| Website | ugen.com |
Wugen is a clinical-stage biotech developing off-the-shelf allogeneic cell therapies for hard-to-treat blood and solid tumors. Its programs target patients with cancers such as relapsed or refractory acute myeloid leukemia and T-cell malignancies. The company's Moneta platform engineers cytokine-induced memory natural-killer cells designed to be more durable and potent than conventional NK therapies.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-09-08 | Funding round | $163.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Funding round, $163.0M | attributed | sec-edgar named as publisher. No document URL on file. |
| Total raised $163.0M | attributed | sec-edgar named as publisher. No document URL on file. |
| Company existence | self-reported | ugen.com, read 2026-06-02 |
| Description | self-reported | ugen.com, read 2026-06-02 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-25Latest round: seed, $163.0M, 2025-09-08 → Funding round, $163.0M, 2025-09-08, sec-edgar, No document URL on file | Latest round | seed, $163.0M, 2025-09-08 → Funding round, $163.0M, 2025-09-08 | sec-edgar, No document URL on file |
Records begin 2026-09-24. All changes